(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/crwe_tech.jpg

Your Technology Source, Your Technology Team

Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more

Contact Us: contact@crwetech.com

www.CRWETech.com

ad2

http://crweworld.com/assets/images/ad/ad4.png

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com

ad5

http://crweworld.com/assets/images/ad/Pathology_Laboratories.png

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.

www.QuestDiagnostics.com






679 Result: Form 10-K

Diplomat Will Dispense ZEJULA(TM) to Treat Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

April 19th, 2017

The nation’s largest independent specialty pharmacy has been selected to the specialty pharmacy panel to dispense ZEJULA™ (niraparib). FLINT, Mich. / CRWE PRESS RELEASE / April 19, 2017 – Diplomat Pharmacy, Inc. (NYSE: DPLO), ha. Read more

Nivalis Therapeutics and Alpine Immune Sciences Agree to Combine

April 18th, 2017

- Plan to Accelerate Development of Novel Immunotherapies Focused on Inflammation and Immuno-Oncology - - Combined Company Well Capitalized with $90 Million in Funding to Advance Discovery and Development - - Existing Investors OrbiMed Advisors. Read more

Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

April 17th, 2017

LOS ANGELES, Calif. / CRWE PRESS RELEASE / April 17, 2017 - Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has scheduled the New Drug Application (NDA) for n. Read more

Abbott and Alere Amend Terms of Merger Agreement

April 16th, 2017

ABBOTT PARK, Ill. and WALTHAM, Mass. / CRWE PRESS RELEASE / April 14, 2017 - Abbott (NYSE: ABT) and Alere Inc. (NYSE: ALR) announced today that the companies have agreed to amend the existing terms of their agreement for Abbott's acquisition of A. Read more

AVEO Announces Submission of Response to Tivozanib Marketing Authorization Application Day 180 List of Outstanding Issues

April 13th, 2017

CAMBRIDGE, Mass. / CRWE PRESS RELEASE / April 13, 2017 - AVEO Oncology (NASDAQ: AVEO) today announced that its European licensee for tivozanib, EUSA Pharma, has submitted responses to the European Medicines Agency (EMA) Day 180 List of Outstanding Is. Read more

Ritter Pharmaceuticals, Inc. Announces End of Phase 2 Meeting with the FDA and Initiates Phase 3 Program Development Activities

April 12th, 2017

Los Angeles, California / CRWE PRESS RELEASE / April 12, 2017 - Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (the “Company”) today, April 12, 2017, announced that the U.S. Food and Drug Administration (FDA) has agreed to schedule an end of. Read more

Kinder Morgan and DCP Midstream Announce Letter of Intent on Development of Gulf Coast Express Pipeline Project

April 11th, 2017

Pipeline solution provides advantageous takeaway capacity opportunity for prolific Permian Basin production Denver, Colo. / CRWE PRESS RELEASE / April 11, 2017 - Kinder Morgan Texas Pipeline LLC (KMTP), a subsidiary of Kinder Morgan, Inc. (NYSE: K. Read more

Alere Achieves FDA Clearance for Alere(TM) Reader Platform and Alere BinaxNOW(R) Influenza A & B Card 2

April 11th, 2017

WALTHAM, Mass. / CRWE PRESS RELEASE / April 11, 2017 - Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, today announced that its Alere™ Reader, a diagnostic analyzer that can be used in both point-of-care and laboratory settings, h. Read more

Uranium Resources Announces Positive Geophysical Results at its Columbus Basin Lithium Project

April 05th, 2017

CENTENNIAL, Colo. / CRWE PRESS RELEASE / April 5, 2017 - Uranium Resources, Inc. (URI) (Nasdaq: URRE; ASX: URI), an energy metals development company, announced today that its independent geophysical consultant has completed the review, integrat. Read more

Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting

April 02nd, 2017

LOS ANGELES, Calif. / CRWE PRESS RELEASE / April 2, 2017 - Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that interim results from the Phase Ib/II FB-10 clinical trial of Puma’s investigational drug PB272 (nera. Read more

Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting

April 02nd, 2017

LOS ANGELES, Calif. / CRWE PRESS RELEASE / April 2, 2017 - Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 (neratinib) were . Read more

Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with HER2-Positive Breast Cancer or HER2-Mutated Cancer

April 02nd, 2017

Caligor Opco LLC to Provide Regulatory and Logistical Management LOS ANGELES, Calif. / CRWE PRESS RELEASE / April 2, 2017 - Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, has initiated an expanded access program (EAP) in the. Read more

miRagen Therapeutics Provides Corporate Update

March 31st, 2017

BOULDER, CO / CRWE PRESS RELEASE / March 31, 2017 - miRagen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today reported recent clinical and fina. Read more

Corindus Announces First Robotic-Assisted PCI Procedures Performed in Asia Using CorPath(R) GRX System

March 31st, 2017

Live Case Transmitted from Fu Wai Hospital to China Interventional Therapeutics Conference in Beijing Waltham, MA / CRWE PRESS RELEASE / March 31, 2017 - Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS), a leading developer of precision vascular . Read more

miRagen Therapeutics Receives Orphan-Drug Designation for MRG-106 for the Treatment of Mycosis Fungoides

March 31st, 2017

BOULDER, CO / CRWE PRESS RELEASE / March 31, 2017 - miRagen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today announced that the U.S. Food. Read more

Load More Content